Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)-Reference-Cited by-同舟云学术

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

Published:2004-07 Issue:21-22 Volume:22 Page:2722-2729
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Davidson E.J,Faulkner R.L,Sehr P,Pawlita M,Smyth L.J.C,Burt D.J,Tomlinson A.E,Hickling J,Kitchener H.C,Stern P.L

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference22 articles.

1. Vulval intraepithelial neoplasia: current perspectives;Jones;Eur. J. Gynaecol. Oncol.,2001

2. VIN 3: a clinicopathologic review;McNally;Int. J. Gynecol. Cancer,2002

3. Vulval intraepithelial neoplasia—management and outcome;Shafi;Br. J. Obstet. Gynaecol.,1989

4. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy;Abdel-Hady;Cancer Res.,2001

5. Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women;Davidson;Cancer Res.,2003

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral vector-based therapeutic HPV vaccines;Clinical and Experimental Medicine;2024-08-28

2. Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies;Molecular Therapy;2024-07

3. A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity;npj Vaccines;2024-06-26

4. Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies;Life Science Alliance;2024-03-21

5. Progress in the development of vaccines against human papillomavirus;Oncogenic Viruses;2023